Detailed Information

Cited 12 time in webofscience Cited 12 time in scopus
Metadata Downloads

Multicenter comparison of PEG-IFN alpha 2a or alpha 2b plus ribavirin for treatment-naive HCV patient in Korean population

Authors
Jin, Young-JooLee, Jin-WooLee, Jung IlPark, Sang HoonPark, Choong KeeKim, Young SeokJeong, Sook-HyangKim, Yun SooKim, Ju HyunHwang, Seong GyuRim, Kyu SungYim, Hyung JoonCheong, Jae YounCho, Sung WonLee, June SungPark, Young MinJang, Jeong WonLee, Chun KyonSohn, Joo HyunYang, Jin MoHan, Seungbong
Issue Date
29-Apr-2013
Publisher
BioMed Central
Keywords
Chronic hepatitis C; Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Ribavirin; Sustained virological response
Citation
BMC Gastroenterology, v.13
Indexed
SCIE
SCOPUS
Journal Title
BMC Gastroenterology
Volume
13
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10798
DOI
10.1186/1471-230X-13-74
ISSN
1471-230X
Abstract
Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naive chronic HCV patients. Patients received PEG-IFN alfa-2a (180 mu g/week; n=402) or PEG-IFN alfa-2b (1.5 mu g/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (<= 50 and >50), HCV viral load (IU/mL) (<= 7x10(5) and >7x10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE